novo nordisk stock zacks

News

Novo Nordisk, NVO

Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned +4.

Opinion

The Motley Fool on MSN · 2d

Why Novo Nordisk Stock Plummeted Today

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, patient investors could find opportunity as the stock falls.

Fintel on MSN · 21h

HSBC Downgrades Novo Nordisk A (NVO)

Fintel reports that on July 31, 2025, HSBC downgraded their outlook for Novo Nordisk A (NYSE:NVO) from Buy to Hold. Analyst Price Forecast Suggests 110.20% Upside As of July 17, 2025, the average one-year price target for Novo Nordisk A is $98.

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Zacks Investment Research on MSN1d

Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note

In the latest trading session, Novo Nordisk (NVO) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a ...

NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?

Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...

Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know

Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...

The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

Nasdaq17d

Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock? - Nasdaq

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable ...

3don MSN

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%.

The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results